Cytokinetics, Incorporated (FRA:KK3A)

Market Cap	7.60B +34.7%
Revenue (ttm)	59.23M -21.1%
Net Income	-782.52M
EPS	-6.41
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	54.92
Previous Close	54.92
Day's Range	54.58 - 54.92
52-Week Range	46.60 - 75.62
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 4, 2026

About Cytokinetics

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in h...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 673
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: KK3A

Financial Performance

In 2025, Cytokinetics's revenue was $88.04 million, an increase of 376.56% compared to the previous year's $18.47 million. Losses were -$784.96 million, 33.2% more than in 2024.

Financial numbers in USD

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 24, 2026

Data Sources Report a data error